20 articles
CGM technology reveals glucose patterns that could transform diagnosis and treatment across kidney disease, sleep disorders, and more.
Study reveals CGMs consistently overestimate glycemic responses, potentially misclassifying food glycemic index ratings.
The FDA cleared Dexcom's Stelo CGM for children 2+, offering real-time glucose tracking without a prescription for young users.
Children who start continuous glucose monitoring within 6 months of type 1 diabetes diagnosis show significantly better glycemic control 3 years later.
CGM data combined with other factors accurately identifies high-risk individuals, enabling earlier intervention strategies.
Glycated albumin and fructosamine perform as well as HbA1c for detecting hyperglycemia when compared to continuous glucose monitoring.
Case report reveals continuous glucose monitors can trigger anxiety, nausea, and other symptoms when used inappropriately.
New wearable and non-invasive glucose monitors are transforming diabetes care — here's what's available and how they work.
New review shows continuous glucose monitors and insulin pumps significantly improve pregnancy outcomes for diabetic mothers.
Framingham Heart Study reveals how carbohydrate quality and overall diet patterns affect continuous glucose fluctuations in 677 adults without diabetes.
A software flaw in True Metrix glucose meters causes dangerous misreadings. FDA urges diabetics to switch devices immediately.
Adaptyx Biosciences unveils a wearable that monitors cortisol in real time, capturing hormonal rhythms conventional tests routinely miss.
New review reveals how C-peptide measurement is advancing diabetes care through improved testing methods and clinical applications.
A new health tech partnership merges diabetes management with cardiovascular monitoring to tackle cardiometabolic risk before complications arise.
A clinically validated wearable ultrasound sensor monitors blood pressure non-invasively and continuously across real-world and ICU settings.
Phase III trials show once-weekly CagriSema outperforms placebo on HbA1c and body weight in multiple type 2 diabetes populations.
Synthetic biology meets wearable tech — engineered living cells and cell-free systems now enable continuous, adaptive monitoring of hormones, pathogens, and drugs.
Editorial explores how interdisciplinary sensor innovations are revolutionizing continuous health tracking and preventive care.
A landmark RCT of 5,047 type 2 diabetics finds GLP-1 agonists linked to fewer hospitalizations than other second-line therapies.
Dr. Michael Snyder reveals how continuous glucose monitors and smartwatches can detect illness onset and optimize metabolic health.
